Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Interest Expenses (2019 - 2022)

Keros Therapeutics' Interest Expenses history spans 4 years, with the latest figure at $1000.0 for Q1 2022.

  • For Q1 2022, Interest Expenses changed 0.0% year-over-year to $1000.0; the TTM value through Dec 2022 reached $1000.0, down 75.0%, while the annual FY2022 figure was $1000.0, 75.0% down from the prior year.
  • Interest Expenses reached $1000.0 in Q1 2022 per KROS's latest filing, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3000.0 in Q3 2019 to a low of $1000.0 in Q2 2020.
  • Average Interest Expenses over 4 years is $1500.0, with a median of $1000.0 recorded in 2020.
  • The largest YoY upside for Interest Expenses was 0.0% in 2020 against a maximum downside of 50.0% in 2020.
  • A 4-year view of Interest Expenses shows it stood at $3000.0 in 2019, then crashed by 66.67% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022.
  • Per Business Quant, the three most recent readings for KROS's Interest Expenses are $1000.0 (Q1 2022), $1000.0 (Q4 2021), and $1000.0 (Q3 2021).